<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00498836</url>
  </required_header>
  <id_info>
    <org_study_id>CP4055-203</org_study_id>
    <nct_id>NCT00498836</nct_id>
  </id_info>
  <brief_title>Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma</brief_title>
  <official_title>A Multicentre, Dose Finding, Phase II Study of CP-4055 in Combination With Sorafenib in Patients With Metastatic Malignant Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Clavis Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Clavis Pharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with metastatic malignant melanoma will receive CP-4055 200 mg/m2/day intravenously&#xD;
      (IV) on Day 1-5 every four weeks and sorafenib 400 mg b.i.d. (twice daily) every day until&#xD;
      complete response or disease worsening/progressing.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multicentre clinical study conducted in the USA and in Europe. It is an open label&#xD;
      study designed to investigate objective tumor response, the time to progression (TTP) and the&#xD;
      duration of tumor response in patients with metastatic malignant melanoma when treated with&#xD;
      CP-4055 in combination with sorafenib (Nexavar®). The safety and tolerability of the&#xD;
      treatment will also be assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2007</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>• Objective tumour response</measure>
    <time_frame>October 2008</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Time to progression</measure>
    <time_frame>October 2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Duration of tumour response</measure>
    <time_frame>October 2008</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Safety and tolerability of treatment</measure>
    <time_frame>October 2008</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">18</enrollment>
  <condition>Malignant Melanoma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-4055</intervention_name>
    <description>CP-4055 5mg/mL for infusion, dose: 200 mg/m2/day, schedule d1-5 q4w, 30 minutes IV infusion</description>
    <other_name>ELACYT (TM)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sorafenib (Nexavar)</intervention_name>
    <description>Sorafenib 200 mg tablets, dose: 400 mg/day, daily dosing</description>
    <other_name>Nexavar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with histological or cytological confirmed stage IV or unresectable stage III&#xD;
             non-ocular malignant melanoma who have or have not undergone prior chemotherapy for&#xD;
             the treatment of melanoma&#xD;
&#xD;
          2. Measurable disease according to Response Criteria In Solid Tumors (RECIST)&#xD;
&#xD;
          3. Performance Status 0 - 1 according to ECOG (Eastern Cooperative Oncology Group)&#xD;
             Performance Status&#xD;
&#xD;
          4. Age 18 years or more&#xD;
&#xD;
          5. Life expectancy &gt; 3 months&#xD;
&#xD;
          6. Signed informed consent&#xD;
&#xD;
          7. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically&#xD;
             sterile) must have a negative serum or urine pregnancy test within 2 weeks prior to&#xD;
             beginning treatment on this study&#xD;
&#xD;
          8. Male and female patients must use acceptable contraceptive methods for the duration of&#xD;
             time on study, and males also for 3 months after the last CP-4055 dose&#xD;
&#xD;
          9. Adequate haematological and biological functions&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known brain metastases&#xD;
&#xD;
          2. Diagnosis of ocular malignant melanoma&#xD;
&#xD;
          3. Radiotherapy to more than 30 % of bone marrow&#xD;
&#xD;
          4. Participation in another therapeutic clinical study within 30 days of enrolment or&#xD;
             during this clinical study&#xD;
&#xD;
          5. Requirement of concomitant treatment with a non-permitted medication:&#xD;
&#xD;
               -  Alternative drugs&#xD;
&#xD;
               -  High doses of vitamins&#xD;
&#xD;
          6. History of allergic reactions to ara-C or egg&#xD;
&#xD;
          7. History of allergic reactions attributed to compounds of similar chemical or&#xD;
             biological composition to sorafenib&#xD;
&#xD;
          8. Presence of any serious concomitant systemic disorders incompatible with the clinical&#xD;
             study (e.g. uncontrolled inter-current illness including ongoing or active infection)&#xD;
&#xD;
          9. Presence of any significant central nervous system or psychiatric disorder(s) that&#xD;
             would hamper the patient's compliance&#xD;
&#xD;
         10. Pregnancy, breastfeeding or absence of adequate contraception for both male and female&#xD;
             fertile patients&#xD;
&#xD;
         11. Known positive status for HIV and/or hepatitis B or C&#xD;
&#xD;
         12. Drug and/or alcohol abuse&#xD;
&#xD;
         13. Any reason why, in the investigator's opinion, the patient should not participate&#xD;
&#xD;
         14. Prior treatment with CP-4055 and/or sorafenib&#xD;
&#xD;
         15. Significant history of cardiac disease, including any of the following:&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Congestive heart failure&#xD;
&#xD;
               -  Myocardial infarction within the past 6 months&#xD;
&#xD;
               -  Unstable ventricular arrhythmia&#xD;
&#xD;
               -  Other cardiac arrhythmia&#xD;
&#xD;
         16. Condition that impairs ability to swallow pills&#xD;
&#xD;
         17. Tendency of bleeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Svein Dueland, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Norwegian Radium Hospital, Oslo, Norway</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center, Institute for Drug Development</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Norwegian Radium Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>NO-0310</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lund University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Umeå University Hospital</name>
      <address>
        <city>Umeå</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uppsala University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>July 9, 2007</study_first_submitted>
  <study_first_submitted_qc>July 9, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2007</study_first_posted>
  <disposition_first_submitted>August 28, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>August 28, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">September 12, 2013</disposition_first_posted>
  <last_update_submitted>August 28, 2013</last_update_submitted>
  <last_update_submitted_qc>August 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CP-4055</keyword>
  <keyword>Elacyt</keyword>
  <keyword>Cancer</keyword>
  <keyword>Metastatic</keyword>
  <keyword>Malignant melanoma</keyword>
  <keyword>Combination treatment</keyword>
  <keyword>Sorafenib</keyword>
  <keyword>Nexavar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sorafenib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

